Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.
Deiana C., Fabbri F., Tavolari S., Palloni A., Brandi G. (2023). Improvements in Systemic Therapies for Advanced Malignant Mesothelioma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(13), 10415-10436 [10.3390/ijms241310415].
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
Deiana C.;Fabbri F.;Tavolari S.;Palloni A.;Brandi G.
2023
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
